Paradigm Genetics and TissueInformatics are teaming up in an effort to discover novel biomarkers for chronic liver disease, the companies announced Wednesday.
Paradim is to perform studies on tissue, urine and plasma to identify biochemical profiles that are disease specific. TissueInformatics will perform automated tests to determine changes in tissue structure. The companies then will integrate and study the data to see what biomarkers may be found that could signal to presence and progression of liver disease, the firms said in a joint statement.
Financial terms were not disclosed.
TissueInformatics, which is based in Pittsburgh, also will provide Paradigm with data for a forthcoming toxicology study.
“This relationship represents an important step in the building of Paradigm’s healthcare business and strengthens our offerings in predictive toxicology and disease staging,” said Heinrich Gugger, president and chief executive officer of Paradigm.